Damora Therapeutics (DMRA) Liabilities and Shareholders Equity (2019 - 2026)

Damora Therapeutics (DMRA) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $535.4 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 3384.82% year-over-year to $535.4 million; the trailing twelve-month figure through Mar 2026 stood at $820.4 million (up 886.41% YoY), and the FY2025 full-year result was $260.5 million, up 1420.7% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $535.4 million, up from $260.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $535.4 million in Q1 2026 and bottomed at $10.7 million in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $50.0 million (2023), against an average of $88.5 million.
• The widest annual swing landed in 2024, when Liabilities and Shareholders Equity tumbled 55.18%; it then soared 3384.82% in 2026.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $73.2 million in 2022, then plunged by 47.77% to $38.2 million in 2023, then sank by 55.18% to $17.1 million in 2024, then surged by 1420.7% to $260.5 million in 2025, then surged by 105.52% to $535.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $535.4 million (Q1 2026), $260.5 million (Q4 2025), and $10.7 million (Q3 2025), per Business Quant data.

Peer Comparison